DORFSTRASSE 29, ZUG, V8
Other Events
MoonLake Reports Positive Results from Phase 3 Sonelokimab Trial and Q2 2026 Financials
MoonLake Immunotherapeutics Enters Underwriting Agreement for 9M Shares
Investor Day June 22nd, 2026
MoonLake Immunotherapeutics Increases Equity Incentive Plan Shares by 5 Million
Master Commercial Supply Agreement with Vetter Pharma International
Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence